The formation of lysophosphatidylinositol phosphate in human platelet microsomes

Plasma fatty acid levels in South African interethnic male high school pupils at different ultimate risks of coronary heart disease

While coronary heart disease (CHD) is responsible for about a quarter of deaths in South African white, coloured and Indian populations, the rate is very low in the black population. Dietary risk factors for CHD include high intakes of saturated fatty acids and cholesterol, with low intakes of mono and polyunsaturated fatty acids. In a characterization study, plasma fatty acid profiles have been determined in seven groups of high school pupils aged 16-18 years, namely, white, rural black, urban black and middle-class and lower socio-economic class coloureds and Indians. Plasma fatty acids were measured by gas liquid chromatography in 20 subjects from each group. Contrary to expectation, urban and rural black pupils had the highest mean molar composition of saturated fatty acids, largely myristic (14:0) and palmitic (16:0) acids. Rural blacks and middle-class coloureds had the highest molar percentage composition of monounsaturated fatty acids, primarily oleic acid (18:1). Again unexpectedly, white, coloured and Indian groups had the highest level of polyunsaturated fatty acids, due entirely to linoleic acid (18:2). As the findings are unrelated to proneness to CHD mortality in the particular communities studied, plasma fatty acid levels are not predictive of the disease. Epidemiologically, there are many examples of lack of correlation in serum lipid levels and proneness to CHD.

Platelet hyperreactivity in hyperlipidaemia with specific reference to platelet lipids and fatty acid composition

Platelet function after thrombin stimulation, the fatty acid composition of individual phospholipids, and levels of lipid components (cholesterol, cholesterol ester, phospholipids and triglycerides) were determined in total membranes of platelets from hyperlipidaemic (HL) and control subjects. Platelet aggregation, thromboxane (TX) B2 production and serotonin release was significantly greater in HL patients than in controls. Levels of platelet cholesterol, total phospholipids, cholesterol ester and triglycerides, were significantly higher in the HL patients. Small differences between the two groups were observed for the phospholipid fatty acid patterns. However, levels of arachidonic acid (AA) were significantly higher in phosphatidylinositol (PI) of HL patients (40.01 +/- 6.59 mol%) as compared to the controls (31.52 +/- 9.91 mol%) (P = 0.002). The higher levels of AA in PI, which is considered a donor pool for eicosanoid synthesis, may be an additional mechanism for the well documented platelet hyperfunction and greater TXB2 production in hyperlipidaemic subjects.

In vivo formation of polyphosphoinositide isomers and association with progression of murine polycystic kidney disease

Polyphosphoinositide isomers have been demonstrated to be important mediators of cell proliferation in vitro. The present study demonstrates, for the first time, the in vivo formation of the novel isomer, phosphatidylinositol(3)phosphate, in the kidney and liver of intact animals following intraperitoneal administration of [3H]myo-inositol. The formation of renal [3H]phosphatidylinositol(3)phosphate relative to total [3H]phosphatidylinositol-phosphate was positively correlated with cyst proliferation and renal enlargement in a murine model of polycystic kidney disease. Furthermore, despite no difference in the formation of renal [3H]phosphatidylinositol(4)phosphate, a markedly lower accumulation (by 48%) of [3H]phosphatidylinositol(4,5)bisphosphate was observed in the diseased animals as compared to controls. These results indicate that further studies on the in vivo formation of specific polyphosphoinositide isomers in disease states characterized by abnormal growth and oncogene expression are warranted.

Phosphorylation of lysophosphatidylinositol by carrot membranes

sn-1 Palmitoyl lysophosphatidylinositol is found in carrot suspension culture cells and can be phosphorylated to [32P]lysophosphatidylinositol monophosphate (LPIP) when [gamma 32P]ATP is added to isolated membranes. Based on in vivo labeling studies, [3H]inositol sn-1 palmitoyl LPIP was found predominantly in the plasma membrane-rich fraction or upper phase isolated by aqueous two-phase partitioning and LPI was found in the intracellular membrane-rich fraction or lower phase (Wheeler and Boss, Plant Physiol. 85, 389-392, 1987). While both membrane fractions phosphorylated LPI in vitro, the apparent Km for LPI in the intracellular membrane fraction was 180 microM and for the plasma membrane was 580 microM. When cells were treated with the ionophore, monensin, the percentage of [3H]inositol LPIP increased in the whole cell lipid extract. However, the monensin treatment decreased the amount of [3H]inositol LPIP and PIP recovered in the plasma membrane fraction relative to the sum of the individual lipid, [3H]inositol LPIP or PIP, respectively, recovered in both membrane fractions.

BW755C or staurosporine inhibits collagen-stimulated phosphoinositide phosphorylation in platelets

Stimulation of platelets by collagen results in increased formation of the polyphosphoinositides, phosphatidylinositol phosphate (PtdInsP) and phosphatidylinositol bisphosphate (PtdInsP2) through stimulation of phosphoinositide kinase activities. We investigated a possible regulatory role of endogenous thromboxane formation and protein kinase C (PKC) activation in the induction of phosphoinositide phosphorylation following collagen stimulation, as well as following stimulation by the thromboxane mimetic, U-46619. Human platelets were prelabeled with [3H]inositol and stimulated with collagen (2 micrograms/mL) or U-46619 (1 microM), in the absence or presence of either the cyclo-oxygenase/lipoxygenase inhibitor, BW755C, or staurosporine, a putative inhibitor or PKC. Collagen stimulation resulted in a time-dependent increase in [3H]inositol-labeled PtdInsP and PtdInsP2 which was completely inhibited in the presence of BW755C. Addition of U-46619 to BW755C-treated, collagen-stimulated platelets restored the increased polyphosphoinositide formation. Stimulation of platelets with U-46619 alone also resulted in increased formation of [3H]PtdInsP and [3H]PtdInsP2, but this was not affected by the presence of BW755C. These results suggest that the collagen-induced activation of phosphoinositide kinases was dependent upon thromboxane formation, but that U-46619-induced phosphoinositide formation was rather independent of further thromboxane production. Pretreatment of platelets with staurosporine, prior to agonist addition, completely blocked the collagen-stimulated rise in radiolabeled PtdInsP and the U-46619-induced PtdInsP and PtdInsP2 generations, suggesting that protein kinase, possibly PKC, may play a role in the activation of phosphoinositide kinases by these agonists.

The effect of dietary zinc deficiency on the lipid composition of the rat erythrocyte membrane

The effect of dietary zinc deficiency in the rat on the lipid composition of the erythrocyte membrane was determined. Weanling male Wistar rats were fed an egg white-based diet containing less than 1.0 mg Zn/kg diet ad libitum. Control rats were either pair-fed or ad libitum-fed the basal diet supplemented with 100 mg Zn/kg diet. A zinc refed group was fed the -Zn diet until day 18 and then pair-fed the +Zn diet until day 21. The voluntary feed restriction associated with dietary zinc deficiency resulted in erythrocyte membranes that had depressed phospholipid/protein and elevated cholesterol/phospholipid ratios. Similarly, all feed restricted groups had elevated 22-carbon n-3 polyunsaturated fatty acids (PUFA) and depressed 22-carbon n-6 PUFA concentrations in alkenyl-acyl and diacyl glycerophosphoethanolamine, phosphatidylserine and phosphatidylcholine; they also had depressed 24:2n-6 levels in sphingomyelin. The relative concentrations of phospholipids in the membrane was similar between -Zn and +Zn (ad libitum) groups; however, the -Zn group had significantly less phosphatidyl-serine relative to +Zn (pair-fed) controls.

Methylmalonic acid metabolism and nervous-system fatty acids in cobalamin-deficient fruit bats receiving supplements of methionine, valine and isoleucine

Cobalamin neuropathy was produced in Cape fruit bats (Rousettus aegyptiacus) by a cobalamin-free diet combined with intermittent exposure to nitrous oxide, which inactivates cobalamin. Cobalamin-deficient bats had low hepatic methylmalonyl-CoA mutase holoenzyme activity, with elevated plasma and urinary methylmalonic acid levels. No significant changes could be demonstrated in the concentration of odd- or branched-chain fatty acids in the nervous system. Supplementation of the cobalamin-free diet with methionine, valine or isoleucine delayed the onset of neuropathy, despite persistence of methylmalonic acid accumulation. Supplementation with any of the three amino acids was associated with elevation of hepatic methionine concentration. The action of valine and isoleucine in delaying the onset of neuropathy can be explained by their methionine-sparing effect. These results emphasize the central role of methionine in the cobalamin neuropathy and do not support the hypothesis that the neuropathy is related to an effect of cobalamin deficiency on the propionic acid pathway.

Effect of genistein, a tyrosine kinase inhibitor, on U46619-induced phosphoinositide phosphorylation in human platelets

Recent evidence suggests that the agonist-induced formation of phosphatidylinositol 4-phosphate (PIP) and phosphatidylinositol 4,5-bisphosphate (PIP2) via PI and PIP kinases may play an important role in transmembrane signalling. In the present work, the effect of genistein, a specific inhibitor of protein-tyrosine kinase, on phosphoinositide phosphorylation was studied in human platelets stimulated with the endoperoxide analogue, U46619. At 100 microM concentration, genistein, but not the related compounds, flavone and biochanin A, which possess only weak anti-protein-tyrosine kinase activity, significantly inhibited the U46619-induced accumulation of [3H]PIP (by 71%) and [3H]PIP2. These data suggest that phosphoinositide phosphorylation may be regulated, in part, by tyrosine phosphorylation in U46619-stimulated platelets.

Effect of albumin-bound DHA on phosphoinositide phosphorylation in collagen stimulated human platelets

The effect of exogenous albumin-bound docosahexaenoic acid (22:6n-3) (DHA), arachidonic acid (20:4n-6) (AA), and eicosapendaenoic acid (20:5n-3) (EPA) on phosphoinositide metabolism following collagen stimulation was studied using [3H]inositol prelabelled platelets. Collagen stimulation (3 min, 1.8 micrograms/ml) increased the labelling of both phosphatidylinositol 4-monophosphate (PIP), and phosphatidylinositol 4,5-biphosphate (PIP2). Of the fatty acids tested, only pre-incubation (2 min) with DHA (20 microM) significantly attenuated the collagen-induced increased PIP and PIP2 labelling; EPA was without effect, while AA enhanced PIP labelling. Forty microM DHA was less effective at attenuating the increased PIP and PIP2 labelling even though this concentration of DHA resulted in greater inhibition of platelet aggregation. Neither concentration of DHA attenuated the increased polyphosphoinositide labelling resulting from stimulation by the endoperoxide analogue U46619, or the phorbol ester, PMA. These data suggest that the effect of DHA on attenuating the increased PIP and PIP2 labelling following collagen stimulation likely occurs before thromboxane receptor occupancy, may not occur at the level of protein kinase C activation, and could be mediated in part via a lessened synthesis of thromboxane A2.

Effects of aristolochic acid on phospholipase A2 activity and arachidonate metabolism of human neutrophils

Aristolochic acid is an alkaloid which has recently been shown to have anti-inflammatory activity against edema in mouse foot pads induced by phospholipases A2 from human synovial fluid. The present study has investigated the effects of aristolochic acid on phospholipase activity and arachidonic acid mobilization in human neutrophils. We find that aristolochic acid is a dose-dependent inhibitor of the calcium-dependent neutral active phospholipase A2 isolated from human neutrophils. As much as 90% of the A23187-stimulated release of previously incorporated [3H]arachidonate from intact neutrophils is inhibited by aristolochic acid; the effect is dose-dependent, with an IC50 of 40 microM, and quite rapid, with near maximal inhibition within 5 min. Aristolochic acid inhibits the A23187-stimulated loss of [3H]arachidonate from both choline- and inositol-phospholipids. Decreased release of free [3H]arachidonate is accompanied by a concomitant decrease in synthesis of [3H]leukotriene B4 and [3H]hydroxyeicosatetraenoic acids. Furthermore, aristolochic acid also inhibits the A23187-stimulated synthesis of [3H]alkylacetylglycerophosphocholine from cellular [3H]alkylacylglycerophosphocholine. These results indicate that aristolochic acid is an effective inhibitor of the A23187-stimulated phospholipase A2 activity in human neutrophils.